Sign in
AFMDQ Stock Price, Chart, Stats & News
Affimed N.V.
Save
Affimed N.V. (AFMDQ) does not currently pay a dividend.
1,639
Market cap
–
Current P/E
–
Forward P/E
AFMDQ chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Affimed N. V. operates as a clinical-stage biopharmaceutical firm, dedicated to the discovery and advancement of immunotherapies targeting cancer across both the United States and Germany. Its primary therapeutic candidates include AFM13, which has successfully concluded Phase 2 trials for CD30-positive lymphoma, Phase 1b for Hodgkin lymphoma, and Phase 2b clinical evaluation for peripheral T-cell lymphoma.
Similar securities
Based on sector and market capitalization
Report issue